VALNEVA
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.
VALNEVA
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Saint-herblain, Pays De La Loire, France
Country:
France
Website Url:
http://www.valneva.com
Total Employee:
501+
Status:
Active
Contact:
33 2 28 07 37 10
Email Addresses:
[email protected]
Total Funding:
786.24 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro SPF Apple Mobile Web Clips Icon WordPress LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Ingenia Therapeutics
Ingenia Therapeutics provider of undisclosed products and services based in Cambridge, Massachusets.
KetoSwiss
KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-02-10 | Crucell Sweden | Crucell Sweden acquired by Valneva | N/A |
Investors List
Horizon Europe
Horizon Europe investment in Grant - Valneva
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations investment in Grant - Valneva
Deerfield
Deerfield investment in Post-IPO Debt - Valneva
OrbiMed
OrbiMed investment in Post-IPO Debt - Valneva
Bpifrance
Bpifrance investment in Post-IPO Equity - Valneva
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Valneva
Pfizer
Pfizer investment in Post-IPO Equity - Valneva
Deerfield
Deerfield investment in Post-IPO Debt - Valneva
OrbiMed
OrbiMed investment in Post-IPO Debt - Valneva
Scottish Enterprise
Scottish Enterprise investment in Grant - Valneva
Key Employee Changes
| Date | New article |
|---|---|
| 2024-05-20 | Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer |
| 2023-03-02 | Valneva reports more data on Covid-19 vaccine; ClinChoice buys a CRO |
| 2022-11-17 | Valneva Appoints Dipal Patel as Chief Commercial Officer |
Official Site Inspections
http://www.valneva.com Semrush global rank: 1.15 M Semrush visits lastest month: 23.84 K
- Host name: sl71.web.hostpoint.ch
- IP address: 217.26.52.50
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Valneva"
Home - Valneva
Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet …See details»
Careers - Valneva
Valneva’s success stems from the dedication and expertise of more than 700 employees. Valneva is an international company that prides itself in providing its workforce the opportunity for personal growth and development, while …See details»
Valneva SE - Wikipedia
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. See details»
Valneva - Crunchbase Company Profile & Funding
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for …See details»
Our Global Operations - Valneva annual business report
Mar 20, 2024 · Valneva’s manufacturing network has been operating and producing licensed vaccines for more than ten years. The two main manufacturing sites in Scotland and Sweden …See details»
Valneva - Org Chart, Teams, Culture & Jobs - The Org
View Valneva's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Valneva - LinkedIn
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.See details»
Our Team - Valneva
Valneva’s Executive Committee is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills. Thomas Lingelbach was CEO of Intercell and founding President and CEO of Valneva.See details»
Corporate Social Responsibility - Valneva annual business report
Valneva has defined long-term responsible business commitments, which reflect global health needs and sit across four key focus areas. Our four pillars are the foundation for our Corporate …See details»
Valneva Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 · Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. It develops vaccines …See details»
Valneva Supervisory Board Recommends Transition from a Two …
Jun 22, 2023 · Saint-Herblain (France), June 22, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its Supervisory Board has …See details»
Investors - Valneva
Jul 11, 2019 · Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical …See details»
General Public – Valneva Nordic
Valneva är ett vaccinföretag som specialiserat sig pÃ¥ utveckling, tillverkning och kommersialisering av profylaktiska vacciner mot infektionssjukdomar. VÃ¥r vision är att bidra till …See details»
Valneva - LinkedIn
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.See details»
Corporate Governance - Valneva
The members of the Valneva Board of Directors are committed to managing the company transparently, in accordance with the French Middlenext Governance Code for Small and …See details»
Valneva SE (VALN) Stock Price, News, Quote & History - Yahoo …
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.See details»
WHO recommends Valneva's COVID vaccine | Reuters
Aug 18 (Reuters) - The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva's (VLS.PA) COVID-19 vaccine. The UN agency also …See details»
The Valneva VLA2001 COVID-19 vaccine: What you need to know
Aug 18, 2022 · The Valneva vaccine is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has …See details»
Valneva Company Presentation
1 Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government; 2 Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 …See details»
Our Strategy - Valneva
Valneva is focused on utilizing its proven and validated product development capabilities to rapidly advance solutions addressing unmet needs in infectious diseases towards regulatory …See details»